Press releases
- Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
- Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
- Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
- Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
- Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
More ▼
Key statistics
On Friday, ACADIA Pharmaceuticals Inc (DR6:DUS) closed at 17.50, 31.39% above the 52 week low of 13.32 set on May 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.06 |
---|---|
High | 17.50 |
Low | 17.06 |
Bid | 17.07 |
Offer | 17.34 |
Previous close | 17.57 |
Average volume | 37.40 |
---|---|
Shares outstanding | 165.22m |
Free float | 164.38m |
P/E (TTM) | -- |
Market cap | 3.16bn USD |
EPS (TTM) | -0.0129 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 18:31 BST.
More ▼